Institutional practice at our hospital (Boston Children's Hospital) is to culture homografts before implantation during congenital cardiac surgery. Over a 4-year period, 5% (73 of 1376) of these cultures were positive, but the results had minimal clinical impact. Our experience demonstrates that there is limited utility in preimplantation cultures of cardiac homografts.
INTRODUCTION
Orthotopic transplantation of cadaveric cardiac tissue, also referred to as homograft material, was first performed in 1962 [1] . In the United States, human tissue processed and issued for transplantation is subject to regulation by the US Food and Drug Administration (FDA). Tissue banks also can receive accreditation from the American Association of Tissue Banks (AATB), although this process is voluntary and not a substitute for FDA regulation [2, 3] . Given increasing use, US regulatory agencies have collaborated to create more rigorous oversight of tissue transplantation [2] [3] [4] .
Although the practice of culturing homografts before implantation is neither explicitly recommended nor discouraged by private manufacturers, limited data exist on the quality control of homograft processing before release to the consumer [5] . In addition, many details of tissue bank practices remain proprietary [5, 6] .
At our tertiary pediatric academic medical center at Boston Children's Hospital, homografts used for patients who are undergoing congenital cardiac surgery have been routinely cultured before implantation. Given that the value of preimplantation cultures remains unknown, particularly when culture results for patients who are asymptomatic are positive, we sought to describe the microbiologic and clinical outcomes associated with positive preimplantation cardiac homograft cultures to determine whether this practice is useful clinically.
METHODS
We performed a retrospective cohort study of children who received a cardiac homograft that was cultured at the time of surgical implantation at Boston Children's Hospital between January 2010 and March 2014. Patients were initially identified through a listing of all homograft cultures performed; additional information was obtained from electronic medical records and the Boston Children's Hospital cardiac surgery and anesthesia database system.
The primary outcome was the proportion and microbiology of positive homograft culture results. To assess the clinical impact of preimplantation cultures, we recorded whether infectious disease (ID) specialist consultation was obtained, whether a change in antimicrobial therapy was made, and if any additional echocardiograms were performed because of a positive homograft culture result. Ninety days after implantation, we also assessed potential infectious outcomes, including bacteremia, infective endocarditis, and surgical site infection caused by the same organism that was present in the homograft culture.
During the study period, homografts (aortic valves, pulmonary valves, and pulmonary patches) from 2 manufacturers (LifeNet Health (R) Virginia Beach, VA and Cryolife Inc. (R) Kennesaw, Georgia) were used in a variety of congenital cardiac surgery procedures. Homografts packaged in a "double-layer" packaging system were stored frozen and thawed according to manufacturer recommendations. The packaging was warmed via sterile bath, and the outer packing was then removed. A sterile team member then warmed the inner packaging via bath, opened the inner package, and drained the storage fluid. The homograft was then retrieved with forceps and passively rinsed for 5 minutes with 5% dextrose/lactated Ringers solution. If the homograft was not implanted immediately, it was kept moist, cool, and covered. A specimen for culture was then obtained from the homograft, typically by directly swabbing the surface of the homograft. In a minority of the cases, clinicians sent leftover homograft tissue to the laboratory for culture, whereas others sent a swab of the fluid from the inner pouch or the fluid in which the homograft was rinsed.
Swabs (or tissue specimens) received by the microbiology laboratory were subjected to an abbreviated bacterial culture protocol that included planting in chocolate agar and thioglycollate broth (no Gram staining was performed). In the majority of the cases, additional swabs were also planted for fungal culture (performed in-house) and acid-fast bacilli (AFB) staining and culturing (performed at the Massachusetts Department of Public Health William A. Hinton State Laboratory Institute).
The Boston Children's Hospital Institutional Review Board approved the study protocol.
RESULTS
A total of 437 homografts were placed in 388 patients during 426 cardiac surgeries over the study period. Of the 1376 cultures performed, 483 (35%) were bacterial, 435 (32%) were fungal, and 458 (33%) were AFB cultures.
The 483 bacterial cultures were performed for 386 (99.5%) of the 388 patients during 424 operations. Of these specimens, 43 were obtained from a second homograft, and 6 were obtained from a third homograft implanted in parallel, which resulted in a second or third bacterial culture, respectively, for the same patient. Forty-eight cultures were duplicative (ie, the specimens were obtained from homograft material that had already been cultured for the same procedure).
The 435 fungal cultures were performed for 354 (91.2%) of the 388 patients during 384 operations. Of these culture specimens, 34 were obtained from a second homograft, and 6 were obtained from a third homograft. Forty-one of these cultures were duplicative.
The 458 AFB cultures were performed for 373 (96.1%) of the 388 patients during 407 operations. Of these cultures, 38 were obtained from a second homograft, and 6 were obtained from a third homograft. Forty-one of these cultures were duplicative.
Of No duplicative cultures were positive. There were no homografts for which culture results were positive for both bacteria and fungi or for both bacteria and AFB. No differences in the rates of culture positivity according to manufacturer, specimen type (swab vs tissue), or collection method were identified.
In response to positive homograft culture results, antimicrobial agents were changed in 5 (7%) of 72 instances (Table 1) . ID specialist consultation was obtained because of homograft culture results for 2 patients. For 1 of these patients, methicillin-resistant Staphylococcus aureus (MRSA) was identified from the bacterial homograft culture. In consultation with an ID specialist, an initial change from cefazolin to vancomycin and rifampin was recommended. However, given the patient's clinical stability, these antibiotics were ultimately discontinued. For the other patient, AFB were noted as "<1 per field" on an AFB stain of the homograft swab but did not subsequently grow in culture. The ID specialist recommended the addition of an AFB blood culture and additional echocardiography. However, the patient was clinically stable, and only the additional blood culture was performed.
No additional echocardiograms were performed in response to a positive homograft culture. There were no episodes of bacteremia, endocarditis, or surgical site infection caused by the same organism isolated from homograft culture within 90 days of homograft implantation.
DISCUSSION
In this study, we found that 5% of all preimplantation cardiac homograft culture results were positive; when considering only bacterial cultures, 69 (14%) of the 483 cultures were positive. Our most compelling evidence of the limited utility of preimplantation cultures is that positive culture results were not predictive of clinical outcomes, and they led to no changes in clinical management.
To our knowledge, performing cultures of homograft material before implantation is not standard practice, but in informal discussions with US hospital microbiology laboratories, we found that some of them perform such cultures on a case-bycase basis. Preimplantation homograft culturing is performed at some banks internationally and is used as a final measure of quality assurance [6] [7] [8] . Case reports of bacterial, viral, and fungal infections transmitted through organ and tissue transplantation, as well as concern of contamination, offer insight into the motivation for this practice [9] . Although the AATB requires qualitative cultures to be performed at the preprocessing and prepackaging steps, neither the AATB nor the US Centers for Disease Control and Prevention has offered a direct public statement or formal recommendation as to whether homografts should be cultured by the end user before implantation, although the topic has been discussed [10, 11] .
It is uncertain whether the organisms isolated in cultures in our institution were related to manufacturing practices, persistent contamination missed in postprocessing manufacturer cultures, contamination of delivery fluid, contamination during the thawing process, contamination during operator handling of the homograft, or contamination during the collection of samples for homograft culture. The microbiologic profiles of our positive homograft cultures generally comprised skin flora and low-virulence organisms. Despite their potential for pathogenicity, these isolates were not associated with adverse outcomes in our study. However, our findings suggest that attention should be paid to both manufacturer-and consumer-level practices [12] .
Our study did have limitations. Our experience at a tertiary academic children's hospital with a large cardiac surgery service may not be generalizable. Because our study was retrospective, data regarding clinical outcomes and clinician assessments of preimplantation culture results were limited to electronic medical record documentation. We did not explore other implications of the protocol, including material and labor costs for the operating room and microbiology laboratory.
Our work adds to the limited literature regarding the clinical relevance of culture results in tissue banking and implantation practices. To our knowledge, ours is the first study of its kind in a pediatric population. Although the provision of detailed feedback on patient outcomes to tissue banks is a critical aspect of traceability efforts and safety reporting, microbiologic surveillance practices should be considered only if they provide clinically relevant information to tissue banks, hospitals, and patients. In reviewing our experience, we found that positive preimplantation homograft culture results had a minimal impact on clinical management. We believe that there is limited clinical utility in routine preimplantation homograft cultures and anticipate using our findings to implement changes in our institutional practice. 
